Wednesday, June 3, 2020

TAE Life Sciences Finds $30M In Series B Round

Foothill Ranch-based TAE Life Sciences, which is developing boron-based radiation therapy drugs for the treatment of cancer, has raised $30M in what it says is an initial, Series B funding round. The company said the funding comes from a consortium of investors, including ARTIS Ventures. The company said the new funding will allow it to further accelerate development of its products. The company says it is working on parallel development of new boron-10 drugs and a neutron accelerator system, a combination aimed at difficult-to-treat cancers. As part of the funding, the company says it has established a drug development facility in Santa Monica that includes dedicated labs for cell biology and antibody production, medicinal chemistry, and molecular biology. The startup is led by CEO Bruce Bauer. More information »